FMP
NASDAQ
0.15 USD
-0.02 (-13.33%)
Mr. John A. Orwin M.B.A.
Healthcare
Biotechnology
https://www.atreca.com
NASDAQ
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria...
0001532346
US04965G1094
04965G109
835 Industrial Road
650 595 2595
US
90
Jun 20, 2019
0001532346
NASDAQ
Biotechnology
Healthcare
04965G109
US04965G1094
US
0.15
1.17
8.91M
5.94M
-
0.102-1.35
3.67
-
-
-
-
-0.06
-
https://www.atreca.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.